UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...
Findings showed a noninferior immune response for both vaccines when Shingrix and Arexvy were coadministered compared with separate administration (primary endpoint). Both anti-gE antibody ...
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...
Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety ...
PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...
The shingles vaccine is recommended for people 50 and older ... According to a Cleveland Clinic Neuropsychologist The ...
Rhode Island has the highest vaccination rate across the country, while Mississippi was found to have the lowest, a new study ...
The risk for incident gout following RZV exposure was not increased among adults aged 50 years or older, according to study findings.
GSK has launched it's Shingles vaccine in Malaysia and here's all you need to know about it. From what it is, to the side ...
GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of its Herpes Zoster vaccine, Shingrix ...
Among the 461,323 individuals who received at least 1 RZV dose, 1264 experienced new-onset gout within 60 days postvaccination; 302 patients were determined to have incident cases of gout, with no ...